Visilizumab, a novel recombinant immunoglobulin , exhibits a unique mechanism of action targeting selectively the siglec-9 receptor expressed on myeloid cells. This interaction leads to a decrease in neutrophil stimulation , effectively dampening inflammatory responses during severe cellular harm. The clinical application of Visilizumab extends to